Comprehensive characterization of HER2-low breast cancers: implications in prognosis and treatment
Authors:
Open Access
- 15 April 2023
- journal article
- research article
- Published by Elsevier in EBioMedicine
- Vol. 91, 104571
Abstract
No abstract availableKeywords
Funding Information
- Chinese University of Hong Kong
- Health and Medical Research Fund (08190586)
This publication has 40 references indexed in Scilit:
- Trastuzumab emtansine (T-DM1) renders HER2 + breast cancer highly susceptible to CTLA-4/PD-1 blockadeScience Translational Medicine, 2015
- New Insights on COX-2 in Chronic Inflammation Driving Breast Cancer Growth and MetastasisJournal of Mammary Gland Biology and Neoplasia, 2015
- Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myelomaBlood, 2014
- Moderate Immunohistochemical Expression of HER-2 (2+) Without HER-2 Gene Amplification Is a Negative Prognostic Factor in Early Breast CancerThe Oncologist, 2012
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011Annals of Oncology, 2011
- Biology, prognosis and response to therapy of breast carcinomas according to HER2 scoreAnnals of Oncology, 2008
- A Functionally Significant Cross-talk between Androgen Receptor and ErbB2 Pathways in Estrogen Receptor Negative Breast CancerNeoplasia, 2008
- COX-2 Expression in Invasive Breast CancerApplied Immunohistochemistry & Molecular Morphology, 2007
- Regulation of HER-2 oncogene expression by cyclooxygenase-2 and prostaglandin E2Oncogene, 2004
- Cyclooxygenase-2 Is Overexpressed in HER-2/neu-positive Breast CancerJournal of Biological Chemistry, 2002